A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase II open-label trial evaluating the efficacy, and safety of Erbitux in patients with mucinous gastrointestinal adenocarcinoma involving the peritoneal surface.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Collaborator: ImClone LLC
• Treatments: Cetuximab

Criteria

Inclusion Criteria:

• Able to take care of self. Out of bed less than 50% of the day

• Absolute neutrophil count >=1,500

• Platelet count >=100,000

• Total bilirubin count <=1.5 times the upper limit of normal

Exclusion Criteria:

• Prior epidermal growth factor receptor antibody

• Prior treatment with Erbitux

• Other cancers